| Issuer | % of Class | Filed |
|---|---|---|
|
Aterian, Inc.
13D/A
Amendment 1
ATER · 02156U200
|
3.1% |
9/29/2026
Event 9/25/2026
|
|
Aterian, Inc.
13D
ATER · 02156U200
|
95.7% |
9/10/2026
Event 7/17/2026
|
|
Quantum Cyber N.V.
13D/A
Amendment 1
QUCY · N5436L119
|
94.3% |
8/7/2026
Event 8/5/2026
|
|
KALA BIO, Inc.
13D/A
Amendment 1
KALA · 483119301
|
3.9% |
7/2/2026
Event 5/20/2026
|
|
Universal Safety Products, Inc.
13G/A
Amendment 1
UUU · 913821302
|
9.9% |
5/7/2026
Event 1/27/2026
|
|
Mainz Biomed N.V.
13D
QUCY · N5436L119
|
97.4% |
4/28/2026
Event 4/22/2026
|
|
Indaptus Therapeutics, Inc.
13D/A
Amendment 1
INDP · 45339J105
|
47.9% |
3/24/2026
Event 3/23/2026
|
|
Indaptus Therapeutics Inc.
13D
INDP · 45339J105
|
98.0% |
3/2/2026
Event 2/26/2026
|
|
KALA BIO, Inc.
13D
KALA · 483119202
|
5.2% |
2/6/2026
Event 1/30/2026
|
|
NovaBay Pharmaceuticals, Inc.
13D/A
Amendment 2
NBY · 66987P409
|
4.99% |
1/29/2026
Event 10/21/2025
|
|
Universal Safety Products, Inc.
13G
UUU · 913821302
|
6.8% |
1/26/2026
Event 1/16/2026
|
|
NovaBay Pharmaceuticals, Inc.
13D/A
Amendment 1
NBY · 66987P409
|
20.0% |
10/17/2025
Event 10/16/2025
|
|
NovaBay Pharmaceuticals, Inc.
13D
NBY · 66987P409
|
20.0% |
8/26/2025
Event 8/19/2025
|
|
Matinas BioPharma Holdings, Inc.
13G
MTNB · 576810303
|
9.8% |
8/19/2025
Event 8/15/2025
|
|
Cyclacel Pharmaceuticals, Inc.
13D/A
Amendment 2
CYCC · 23254L801
|
0% |
8/8/2025
Event 8/5/2025
|
|
Cyclacel Pharmaceuticals, Inc.
13D/A
Amendment 1
CYCC · 23254L801
|
8.2% |
8/4/2025
Event 7/30/2025
|
|
FiEE, Inc.
13D/A
Amendment 5
MINM · 60365W102
|
35.1% |
3/10/2025
Event 2/18/2025
|
|
Cyclacel Pharmaceuticals, Inc.
13D
CYCC · 23254L801
|
15.8% |
2/28/2025
Event 2/6/2025
|
|
Minim, Inc.
13D/A
Amendment 4
MINM · 60365W102
|
78.3% |
12/31/2024
Event 12/26/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.